Table 1 Characteristics of RCTs included in this systematic review
Source | Country | Study design | Total, n | Subjects intensity | Age (years) mean (SD) | Baseline MMSE mean (SD) | Intervention | Duration | Risk of bias |
|---|---|---|---|---|---|---|---|---|---|
Merce [12] 2020 | Spain and USA | RCT | 322 | Mild to moderate | 69.0 (7.7) | 21.6 (2.6) | PE VS placebo | 6 weeks + 12 months (6 weeks dosing period and 12 months observation period) | L, L, L, L, U, U |
Sha [32] 2019 | USA | RCT | 18 | Mild to moderate | 74.2 (3.84) | 19.39 (3.24) | Young plasma infusions VS placebo | 14 weeks | L, L, L, U, H, U |
NCT00742417 [33] 2017 | Spain and USA | RCT | 37 | Mild to moderate | 67.7 (7.9) | 21.5 (2.8) | PE VS placebo | 21 weeks + 6 months (21 weeks dosing period and 6 months observation period) | L, L, L, U, U, U |
Kile [34] 2017 | USA | RCT | 49 | MCI | 72.3 (7.56) | 26.6 (2.4) | IVIG VS placebo | 104 weeks (10 weeks dosing period and 94 weeks observation period) | L, L, L, L, U, U |
Relkin [23] 2017 | USA and Canada | RCT | 390 | Mild to moderate | 70.3 (9.3) | 21.3 (3.2) | IVIG VS placebo | 78 weeks | L, L, L, U, H, U |
NCT01524887 [24] 2012 | USA | RCT | 261 | Mild to moderate | 70.8 (9.0) | NR | IVIG VS placebo | 78 weeks | L, U, L, L, L, L |
Dodel [35] 2013 | Germany and USA | RCT | 55 | Mild to moderate | 70.1 (8.2) | 21.5 (5.3) | IVIG VS placebo | 24 weeks | L, L, L, L, L, L |
Arial [36] 2014 | Japan | RCT | 16 | Mild to moderate | 72.6 | 20.0 | IVIG VS placebo | 26 weeks (12 weeks dosing period and 14 weeks observation period) | U, U, L, U, U, U |